Drug intelligence / Profile preview

KACM-002

Development stage: Unknown
Lead developer: Beijing Biohealthcare Biotechnology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KACM-002 is an adoptive cell therapy being developed by Beijing Biohealthcare Biotechnology Co., Ltd. for the treatment of solid tumors. It is produced using the company's proprietary MTCA-CTL (Membrane-bound Tumor-associated Cytotoxic T Lymphocyte) platform, which generates T cells with a TCR-T style mechanism to enhance tumor-specific recognition and killing. The therapy involves the engineering of cytotoxic T lymphocytes to express specific receptors that target tumor-associated antigens. KACM-002 is currently undergoing Phase 1 clinical trials in China to evaluate its safety and preliminary efficacy in patients with advanced malignancies.

Beyond the preview

Go deeper on KACM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KACM-002.

Explore the full profile